Health Care & Life Sciences » Biotechnology | Bioinvent International AB

Bioinvent International AB | Balance Sheet

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
64,745.00
45,627.00
39,973.00
226,114.00
133,760.00
68,851
Total Accounts Receivable
8,650.00
16,639.00
8,862.00
37,466.00
8,866.00
23,911
Inventories
205.00
61.00
464.00
1,918.00
2,386.00
2,950
Other Current Assets
3,909.00
4,980.00
3,825.00
5,152.00
5,789.00
6,655
Total Current Assets
77,509.00
67,307.00
53,124.00
270,650.00
150,801.00
102,367
Net Property, Plant & Equipment
3,928.00
2,301.00
1,323.00
5,648.00
19,246.00
18,033
Long-Term Note Receivable
-
4,500.00
-
-
-
-
Total Assets
81,437.00
74,108.00
54,447.00
276,298.00
170,047.00
120,400
Accounts Payable
9,446.00
7,588.00
9,647.00
10,291.00
14,171.00
Other Current Liabilities
22,984.00
14,092.00
15,346.00
35,570.00
25,651.00
Total Current Liabilities
32,430.00
21,680.00
24,993.00
45,861.00
39,822.00
Total Liabilities
32,430.00
21,680.00
24,993.00
45,861.00
39,822.00
Common Equity (Total)
49,007.00
52,428.00
29,454.00
230,437.00
130,225.00
Total Shareholders' Equity
49,007.00
52,428.00
29,454.00
230,437.00
130,225.00
Total Equity
49,007.00
52,428.00
29,454.00
230,437.00
130,225.00
Liabilities & Shareholders' Equity
81,437.00
74,108.00
54,447.00
276,298.00
170,047.00

About Bioinvent International AB

View Profile
Address
Sölvegatan 41
Lund SN 223 70
Sweden
Employees -
Website http://www.bioinvent.com
Updated 07/08/2019
BioInvent International AB engages in the research and development of immuno-regulatory antibodies to treat cancer. Its clinical programs include BI-1206 for non-Hodgkin's lymphoma and chronic lymphatic leukaemia; TB-403 for paediatric brain tumors; and THR-317 for diabetic macular edema. Its technology platforms consist of F.